Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $16.88.

A number of equities research analysts have weighed in on the company. Morgan Stanley restated an "equal weight" rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Monday. Bank of America increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, October 17th. Finally, Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th.

Amicus Therapeutics Stock Up 0.7 %

NASDAQ:FOLD traded up $0.06 on Wednesday, reaching $9.27. The stock had a trading volume of 2,504,613 shares, compared to its average volume of 2,618,857. The company has a 50-day moving average of $9.81 and a 200 day moving average of $10.54. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The stock has a market cap of $2.77 billion, a P/E ratio of -27.26 and a beta of 0.62. Amicus Therapeutics has a 12-month low of $8.78 and a 12-month high of $14.03.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $10,161,054.84. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 22,901 shares of company stock valued at $259,863. Company insiders own 2.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Xponance Inc. raised its holdings in shares of Amicus Therapeutics by 5.3% during the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company's stock valued at $184,000 after buying an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. increased its position in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 1,569 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 1,884 shares during the period. OLD Second National Bank of Aurora acquired a new position in Amicus Therapeutics during the 3rd quarter worth $26,000. Finally, AlphaCentric Advisors LLC grew its stake in shares of Amicus Therapeutics by 1.2% in the third quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company's stock worth $2,189,000 after purchasing an additional 2,500 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.